News
TriSalus' tri-pronged approach may offer new hope to pancreatic and liver cancer patients says CEO
News
2025-03-26
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping
2024-11-10
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer
2024-06-03
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or
2023-06-12
TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meetin
2022-11-15
TriSalus inks SPAC merger to fund cancer trials of pressure-enabled drug delivery technology
2022-11-15
TriSalus inks SPAC merger to fund cancer trials of pressure-enabled drug delivery technology
2022-11-14
TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation
2022-05-23
TriSalus Life Sciences has been named to The Denver Post’s 2022 Top Workplaces list
2022-02-10
TriSalus Life Sciences Expands Clinical Executive Team and Scientific Advisors in Support of Company’s Focus to Overcome Liver and Pancreatic Cancer Treatment Barriers
2022-01-20
TriSalus Life Sciences Announces Collaboration with the University of Colorado Anschutz Medical Campus to Advance Research on Innovative Immuno-oncology Treatments
2022-01-06
Global Liver Institute and TriSalus Life Sciences Partner To Launch “Liver Central,” a New Resource Hub for Liver Cancer Researchers, Clinicians and Patients
2021-11-01
TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases
2021-04-14
TriSalus Life Sciences Presents Data at American Association of Cancer Research Showing Reduced Liver Tumor Burden from Toll-Receptor Agonists
2021-04-08
TriSalus Life Sciences and MD Anderson Announce Strategic Research Collaboration to Evaluate Treatment of Solid Tumors
2021-02-09
TriSalus Life Sciences Receives Expanded Reimbursement Authorization from CMS for TriNav Infusion System
2020-09-23
TriSalus Life Sciences Lays Out Therapeutic Strategy Upon Acquisition of First Therapeutic Candidate
2020-08-03
TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales
2020-02-12
TriSalus Life Sciences and Roger Williams Medical Center Announce Initiation of Phase 1 Clinical Trial for a Novel Delivery Technology That Can Enhance Drug Delivery into Pancreatic Tumors
2020-02-10
TriSalus Life Sciences CEO Mary Szela to Speak on Panel at 2020 BIO CEO & Investor Conference
2019-06-27